GeneVentiv Therapeutics Inc

GeneVentiv Therapeutics Inc. is a privately held gene therapy company based in Raleigh, North Carolina. The company employs two individuals and has reported revenue of $2.5 million. GeneVentiv Therapeutics specializes in developing gene therapies for patients with Hemophilia A and Hemophilia B, including those with inhibitors who are unable to respond to current therapies. Their research focuses on leveraging Adeno Associated Virus (AAV) directed gene therapy and the clotting cascade to overcome the challenge posed by neutralizing antibodies. The company aims to provide a single, life-changing infusion that offers a cure, as opposed to weekly injections of bypass agents. GeneVentiv Therapeutics is in the Investigational New Drug (IND) enabling stage of development, working towards bringing the first effective gene therapy for Hemophilia to market. For more information about GeneVentiv Therapeutics Inc., please visit www.geneventiv.com.